SAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others. For more information, submit a form, email attorney A ...

REGN LAWSUIT ALERT: Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline ...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Regeneron Pharmaceuticals, Inc. (REGN) Shareholders ...

LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENERON PHARMACEUTICALS, INC. (REGN), CLICK HERE BEFORE MARCH 10, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.What Is The Lawsuit About? The complain ...

Shareholders That Lost Money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More ...

Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm ...

REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! ...

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/regeneron-ph ...

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 10, 2025. SO WHAT: If you purchased Regeneron securitie ...

Group 1 - Investors who lost money on Regeneron Pharmaceuticals, Inc. (REGN) are encouraged to contact Levi & Korsinsky regarding a pending class action lawsuit [1] - The class action is aimed at addressing potential losses incurred by investors due to undisclosed information or misleading statements related to Regeneron's performance [1] - The announcement highlights the importance of investor awareness and the legal recourse available for those affected by the company's actions [1] Group 2 - The article emphasizes the ongoing legal challenges faced by Regeneron Pharmaceuticals, which may impact investor confidence and stock performance [1] - It suggests that the outcome of the class action could have significant implications for the company's reputation and financial standing [1] - The situation underscores the broader context of investor protection and corporate accountability within the pharmaceutical industry [1]